Trulieve Cannabis Corp. (TRLV) Stock Analysis and Metrics

Trulieve Cannabis

NYSE: TRLV

$8.97 ▲ +0.04 (+0.45%)

At close: Jul 8, 2026 · 3:32 PM UTC

Financial Ratios

Market Cap1.83 Bn

P/E-22.60

P/S1.57

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)90.10 Mn

Revenue Growth (1y) (Qtr)-3.70

Add ratio to table…

About

Trulieve Cannabis Corp. is a vertically integrated cannabis company and multistate operator engaged in the cultivation processing manufacturing and retail distribution of medical and adult use cannabis products across nine United States. Headquartered in Tallahassee Florida the company operates dispensaries cultivation facilities and processing sites aiming to be the brand of choice for patients and adult consumers in its markets. The company generates revenue primarily…

Investment Thesis

▲ Bull case

Trulieve is uniquely positioned to capitalize on the federal rescheduling of medical marijuana to Schedule III, which creates a structural advantage by removing the punitive Section 280E tax burden and enabling DEA registration for its state-licensed operations. This regulatory shift transforms Trulieve from a heavily taxed operator into a more tax-efficient business model, directly improving profitability without requiring revenue growth. The company's early application for DEA registration under the expedited pathway—available only to applicants within 60 days of rescheduling—demonstrates proactive management positioning to secure licensure swiftly, potentially unlocking manufacturing, distribution, and dispensing rights for Schedule III products ahead of competitors. This first-mover advantage in a newly regulated federal framework could establish Trulieve as the benchmark for compliance and operational excellence in the U.S. medical cannabis space, attracting institutional investors previously deterred by tax and regulatory uncertainty.
Despite flat year-over-year revenue in FY2025, Trulieve generated $272.8 million in operating cash flow, underscoring strong underlying cash generation that is being underappreciated by the market. This cash flow supports strategic initiatives like the $50 million share repurchase program authorized in June 2026, which signals management confidence in intrinsic value and provides downside protection for shareholders. Concurrently, the company's hub strategy continues to expand its footprint, with new dispensary openings in Lutz, Belleview, Lake Wales, DeLand, Boca Raton, Fort Myers, and Tallahassee throughout Q1 and Q2 2026, reinforcing market penetration in Florida—the company's cornerstone market. These investments are not merely maintaining scale but are building toward accelerated growth as medical marijuana gains broader acceptance post-rescheduling, particularly in emerging markets like Georgia and Texas where Trulieve has already secured conditional licensing.
The upcoming NYSE listing under ticker TRLV, effective June 10, 2026, represents a material catalyst that is likely underpriced in current valuations. Uplisting to a major U.S. exchange will significantly enhance liquidity, broaden the investor base to include institutional funds restricted to NYSE-listed securities, and increase visibility and analyst coverage—factors historically correlated with valuation re-rating in cannabis stocks. Management explicitly cited this as a "historic milestone" enabling access to deeper capital markets, which could facilitate future accretive acquisitions or debt reduction. Combined with the share repurchase program and improving adjusted EBITDA margins (36% in Q1 2026 vs. 35% in Q4 2025), the company is demonstrating capital discipline while positioning for long-term value creation, a narrative the market may be overlooking amid short-term earnings volatility.

Trulieve is uniquely positioned to capitalize on the federal rescheduling of medical marijuana to Schedule III, which creates a structural advantage by removing the punitive Section 280E tax burden and enabling DEA registration for its state-licensed operations. This regulatory shift transforms Trulieve from a heavily taxed operator into a more tax-efficient business model, directly improving profitability without requiring revenue growth. The company's early application for DEA registration under the expedited pathway—available only to applicants within 60 days of rescheduling—demonstrates proactive management positioning to secure licensure swiftly, potentially unlocking manufacturing, distribution, and dispensing rights for Schedule III products ahead of competitors. This first-mover advantage in a newly regulated federal framework could establish Trulieve as the benchmark for compliance and operational excellence in the U.S. medical cannabis space, attracting institutional investors previously deterred by tax and regulatory uncertainty.
Despite flat year-over-year revenue in FY2025, Trulieve generated $272.8 million in operating cash flow, underscoring strong underlying cash generation that is being underappreciated by the market. This cash flow supports strategic initiatives like the $50 million share repurchase program authorized in June 2026, which signals management confidence in intrinsic value and provides downside protection for shareholders. Concurrently, the company's hub strategy continues to expand its footprint, with new dispensary openings in Lutz, Belleview, Lake Wales, DeLand, Boca Raton, Fort Myers, and Tallahassee throughout Q1 and Q2 2026, reinforcing market penetration in Florida—the company's cornerstone market. These investments are not merely maintaining scale but are building toward accelerated growth as medical marijuana gains broader acceptance post-rescheduling, particularly in emerging markets like Georgia and Texas where Trulieve has already secured conditional licensing.
The upcoming NYSE listing under ticker TRLV, effective June 10, 2026, represents a material catalyst that is likely underpriced in current valuations. Uplisting to a major U.S. exchange will significantly enhance liquidity, broaden the investor base to include institutional funds restricted to NYSE-listed securities, and increase visibility and analyst coverage—factors historically correlated with valuation re-rating in cannabis stocks. Management explicitly cited this as a "historic milestone" enabling access to deeper capital markets, which could facilitate future accretive acquisitions or debt reduction. Combined with the share repurchase program and improving adjusted EBITDA margins (36% in Q1 2026 vs. 35% in Q4 2025), the company is demonstrating capital discipline while positioning for long-term value creation, a narrative the market may be overlooking amid short-term earnings volatility.

▼ Bear case

Trulieve's core Florida market is showing signs of saturation and competitive pressure, evidenced by four consecutive quarters of year-over-year revenue decline or stagnation, including a 3% drop in Q4 2025 and a 4% drop in Q1 2026. Despite new store openings, the company is failing to translate expansion into top-line growth, suggesting diminishing returns on capital invested in retail footprint expansion. This stagnation occurs even as the company benefits from veterans' discounts and new customer promotions, indicating that promotional activity may be masking underlying demand weakness. The market may be overestimating the durability of Trulieve's market share in Florida, where increasing competition from other multi-state operators and evolving consumer preferences could erode pricing power and same-store sales over time.
The company's financial structure remains burdened by significant tax liabilities, with uncertain tax position liabilities rising to $696.4 million as of March 31, 2026, up from $668.4 million at December 31, 2025—a trend driven by ongoing disputes with tax authorities over Section 280E applicability and state-level tax treatments. While federal rescheduling to Schedule III removes the federal 280E burden, state-level tax risks and potential retroactive assessments remain material and underdiscussed in management commentary. Furthermore, deferred tax liabilities increased to $169.8 million in Q1 2026 from $178.0 million at year-end 2025, reflecting timing differences that could reverse unfavorably. These persistent tax-related liabilities represent a hidden overhang on earnings that could resurface if IRS or state audits result in adverse rulings, particularly given the company's history of significant tax contingencies.
Trulieve's reliance on non-GAAP metrics to portray profitability masks ongoing GAAP losses and volatile earnings quality. The company reported a GAAP net loss of $116.4 million for FY2025, and while adjusted EBITDA was positive at $427.3 million, this figure adds back substantial non-cash and non-recurring items including $66.1 million in campaign and political contributions and $20.5 million in share-based compensation. The continued need for such large adjustments raises concerns about the sustainability of core operations and the quality of earnings. Additionally, the CEO's termination of her 10b5-1 trading plan ahead of the second tranche of scheduled sales may signal internal skepticism about near-term stock performance, despite public optimism about uplisting and rescheduling benefits—a divergence between actions and rhetoric that warrants caution.

Trulieve's core Florida market is showing signs of saturation and competitive pressure, evidenced by four consecutive quarters of year-over-year revenue decline or stagnation, including a 3% drop in Q4 2025 and a 4% drop in Q1 2026. Despite new store openings, the company is failing to translate expansion into top-line growth, suggesting diminishing returns on capital invested in retail footprint expansion. This stagnation occurs even as the company benefits from veterans' discounts and new customer promotions, indicating that promotional activity may be masking underlying demand weakness. The market may be overestimating the durability of Trulieve's market share in Florida, where increasing competition from other multi-state operators and evolving consumer preferences could erode pricing power and same-store sales over time.
The company's financial structure remains burdened by significant tax liabilities, with uncertain tax position liabilities rising to $696.4 million as of March 31, 2026, up from $668.4 million at December 31, 2025—a trend driven by ongoing disputes with tax authorities over Section 280E applicability and state-level tax treatments. While federal rescheduling to Schedule III removes the federal 280E burden, state-level tax risks and potential retroactive assessments remain material and underdiscussed in management commentary. Furthermore, deferred tax liabilities increased to $169.8 million in Q1 2026 from $178.0 million at year-end 2025, reflecting timing differences that could reverse unfavorably. These persistent tax-related liabilities represent a hidden overhang on earnings that could resurface if IRS or state audits result in adverse rulings, particularly given the company's history of significant tax contingencies.
Trulieve's reliance on non-GAAP metrics to portray profitability masks ongoing GAAP losses and volatile earnings quality. The company reported a GAAP net loss of $116.4 million for FY2025, and while adjusted EBITDA was positive at $427.3 million, this figure adds back substantial non-cash and non-recurring items including $66.1 million in campaign and political contributions and $20.5 million in share-based compensation. The continued need for such large adjustments raises concerns about the sustainability of core operations and the quality of earnings. Additionally, the CEO's termination of her 10b5-1 trading plan ahead of the second tranche of scheduled sales may signal internal skepticism about near-term stock performance, despite public optimism about uplisting and rescheduling benefits—a divergence between actions and rhetoric that warrants caution.

Peer Comparison

Companies in the

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	PNMXO	Public Service Co Of New Mexico	194.09 Bn	1,282.29	89.62	5.42 Bn
2	GLD	Spdr Gold Trust	139.39 Bn	-271.66	-	-
3	FISV	Fiserv Inc	27.11 Bn	10.60	1.29	29.18 Bn
4	GLDM	World Gold Trust	25.40 Bn	-1,176.16	-	-
5	PHYS	Sprott Physical Gold Trust	14.64 Bn	3.72	-	-
6	CRBD	Corebridge Financial, Inc.	12.29 Bn	-231.90	0.46	-
7	PSLV	Sprott Physical Silver Trust	11.99 Bn	3.87	-	-
8	EAI	Entergy Arkansas, Llc	8.87 Bn	5.05	0.69	28.56 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password